The Trans Pacific Partnership agreement, labeled a free-trade agreement by some, would actually work to provide large pharmaceutical firms unprecedented advantage against cheaper generic drugs, reducing competition, a POLITICO report concluded. The resulting agreement is by design targeting to enrich the largest pharmaceutical companies, but the unintended consequences could damage the burgeoning U.S. generic pharmaceutical industry. But the TPP's worst impact could be felt by seniors, who may be practically restricted from accessing life saving treatments.

One leaked chapter of the agreement has POLITICO’s head spinning
Working off a leaked copy of...

